Showing results (111-120 of 131) with videos related to
Sort By:
Pageof 14
British Journal of Haematology|July 17, 2021
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignanciesFrancesco Passamonti, Alessandra Romano, Marco Salvini, et al.Haematologica|February 2, 2015
Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study)Morena Caira, Anna Candoni, Luisa Verga, et al.Journal of Hematology & Oncology|April 3, 2023
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registryFrancesco Marchesi, Jon Salmanton-García, Caterina Buquicchio, et al.Blood Advances|April 14, 2023
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA surveyJaap A van Doesum, Jon Salmanton-García, Francesco Marchesi, et al.Therapeutic Advances in Hematology|March 16, 2023
Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registryMonia Marchetti, Jon Salmanton-García, Shaimaa El-Ashwah, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 16, 2021
Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panelClaudio Babiloni, Xianghong Arakaki, Hamed Azami, et al.Frontiers in Immunology|March 13, 2023
Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registryAlessandro Busca, Jon Salmanton-García, Francesco Marchesi, et al.International Journal of Antimicrobial Agents|August 15, 2023
Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registryJon Salmanton-García, Francesco Marchesi, Philipp Koehler, et al.Haematologica|March 6, 2025
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world dataEnrica Antonia Martino, Annalisa Pitino, Massimo Offidani, et al.Leukemia & Lymphoma|November 15, 2023
The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA surveyShaimaa El-Ashwah, Jon Salmanton-García, Yavuz M Bilgin, et al.Pageof 14